A phase II clinical trial conducted in Singapore showed that doxycycline in combination with anti-TB drugs reduced the activity of type 1 collagenase and elastin in the sputum of TB patients and was well tolerated (ClinicalTrials.gov Identifier: NCT02774993) (Miow et al., 2021). This evidence concerns the gene ELN and tuberculosis.